Lifecore Biomedical (LDE) Stock Price & Analysis
LDE Stock Chart & Stats
- Day’s Range
- EUR 5.70 - EUR 5.70
- 52-Week Range
- EUR 3.12 - EUR 7.30
- Previous Close
- EUR 5.70
- Volume
- N/A
- Average Volume (3M)
- 61
- Market Cap
- EUR 217.22M
- Enterprise Value
- EUR 386.59M
- Total Cash (Recent Filing)
- EUR 17.47M
- Total Debt (Recent Filing)
- EUR 142.61M
- Price to Earnings (P/E)
- ―
- Beta
- 1.15
- Next Earnings
- May 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized CDMO Platform
Lifecore’s specialized sterile fill-finish platform addresses complex manufacturing needs for injectable biologics and supports customers across development, production, and quality services. This breadth can deepen customer relationships and create durable value as programs advance toward commercialization.
Long-Term Alcon Contract
The extended Alcon term and contractual purchase commitments improve multi-year revenue visibility and provide a foundation for steadier capacity utilization. A deeper relationship with a major customer may also strengthen Lifecore’s credibility and positioning within specialized manufacturing.
Improved 2026 Cash Generation
Positive operating and free cash flow in 2026 indicates that Lifecore generated cash from its business after several weaker years. If maintained, this improvement could support operations, reduce reliance on external funding, and help finance required investment in manufacturing capabilities.
Bears Say
Highly Leveraged Balance Sheet
High debt relative to the asset base and negative stockholders’ equity materially reduce financial flexibility. This structure can constrain investment and increase refinancing or solvency pressure, making the company more exposed if operating performance weakens or funding conditions become less favorable.
Persistent Unprofitable Operations
Lifecore has not converted its CDMO activity into consistent profitability: revenue is broadly flat, operating losses continue, and a large 2026 net loss followed a reversal from positive earnings in 2024. This volatility limits internally generated capital and weakens earnings visibility.
Inconsistent Cash Flow Quality
Although 2026 cash generation improved, the multi-year pattern remains uneven and free cash flow declined substantially from the prior year. Such inconsistency makes it harder to depend on operations for debt service, expansion spending, and other long-term capital requirements.
Lifecore Biomedical News
LDE FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
What is Lifecore Biomedical’s market cap?
When is Lifecore Biomedical’s upcoming earnings report date?
How were Lifecore Biomedical’s earnings last quarter?
Is Lifecore Biomedical overvalued?
Does Lifecore Biomedical pay dividends?
What is Lifecore Biomedical’s EPS estimate?
How many shares outstanding does Lifecore Biomedical have?
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lifecore Biomedical?
What is the TipRanks Smart Score and how is it calculated?
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Paul Josephs
- Employees
- 382
- Website
- www.lifecore.com
- Address
- 3515 Lyman Boulevard, Chaska, MN, 55318, US
Lifecore Biomedical (LDE) Earnings & Revenues
LDE Company Deck
LDE Earnings Call
Earnings Call SentimentNeutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.
View all DE:LDE earnings summariesLDE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 4 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 12 | 0 | 0 |
